Bacterial Co-infections and Antibacterial therapy in retrospective COVID-19 patients in AL Fallujah General Teaching Hospital
Keywords:Bacterial Co-infections, antibacterial therapy, COVID-19
In order to determine a retrospective study data were collected from all 2031 COVID-19 patients detected
by PCR (nasal swap) from January/ 2020- January /2021 for Fallujah General Teaching Hospital ,which total
number of Positive covid19 were 210 in isolation ward and Negative number of COVID-19 were 1821.The
study condense on bacterial co-infections and antibacterial therapy for this bacteria. Clinical information
were : the genera females were 60 ( 28.5%) and were males 150 (71.4%). microbiological detected isolation
from blood sample through 48hour of 210 COVID-19 patients in isolation ward detected by BACT/ALERT®
Culture Media(1)then cultured on routine bacteriological media according to(2)for positive growth isolated
bacteria then identification were done by biochemical test. The result of bacterial isolation from blood of
patients assumptive co-infections among 210 samples, positive growth isolated of bacteria which were 121
(57,6%) and included S. pneumoniae , S. aureus , S. epidermidis, K. pneumoniae, p. aeroginosa and E. coli
and total negative isolated which indeed enclose 89 (42.3%). Depending on ABS achieve guidelines, the
most commonly used antibiotic way was Meropenem, Azithromycin and Cefixime with a median duration of
6 (range 1–13) days in isolation ward and when using Antibiotic Susceptibility test expressed each resistant
and sensitive bacteria to antibiotic discs for all positive isolate and detected by sensitivity patterns of VITEK2
system to some species as ensuring method, but; the study focus on co-infection had the highest frequency
of Staphylococcus aureus 57 (47.1%) isolates which were resistant to Ciprofloxacin, Chloramphenicol,
Gentamycin, Amikacin, azithromycin, Cefotaxime, tetracycline ,Trimethoprim/ Sulphamethoxazole and
sensitive to Levofloxacin and imipenem.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions